Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients’ data, activity index, and clinimetric scores were collected at baseline (T0), six (T6), twelve (T12), and twenty-four (T24) months following treatment initiation. At six, twelve, and twenty-four months, adverse events and treatment cessation were also recorded. Sixty-eight patients (mean age: 62.2±10.9 years; mean RA duration: 15±9.6 years) were enrolled over a period of 12 weeks. At baseline, twenty-four patients (35.3%) were treated with tofacitinib, and forty-four patients (64.7%) were treated with baricitinib. The baseline mean disease activity was moderate as measured by DAS28- ESR (5.0±1.0), DAS 28 CRP (4.69±0.94), and SDAI (26.87±10.73) score. Before beginning JAKinhibs therapy, thirty-two patients (61.8%) were taking bDMARDs, while the remaining thirty-six (38.2%) were bDMARDs-naïve. The 24-month retention rate for JAKinhibs was 91.1%. Six months after beginning treatment with JAKinhibs, a statistically significant improvement was observed in all evaluated activity indices and clinimetric scores. Improvement was confirmed during the 12- and 24-month follow-up evaluations. The positive correlation between baseline-T6 SDAI delta and discontinuation of JAKinhibs (p=0.02) suggests that RA worsening in the first six months may be a predictor of therapy withdrawal. Patients with RA responded favorably to tofacitinib and baricitinib in this prospective, real-world study from a single center in Southern Italy. Efficacy was observed despite an underlying persistent and treatment-resistant disease..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Reumatismo - 74(2022), 3 |
| Sprache: |
Englisch ; Italienisch |
|---|
| Beteiligte Personen: |
M. Tasso [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Baricitinib |
|---|
| doi: |
10.4081/reumatismo.2022.1511 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ004478304 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ004478304 | ||
| 003 | DE-627 | ||
| 005 | 20230501171102.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4081/reumatismo.2022.1511 |2 doi | |
| 035 | |a (DE-627)DOAJ004478304 | ||
| 035 | |a (DE-599)DOAJ36c0e1477318460fb40c0fe3656af5f6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a ita | ||
| 050 | 0 | |a RC31-1245 | |
| 100 | 0 | |a M. Tasso |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The primary objectives of the study were to evaluate the efficacy and safety of tofacitinib and baricitinib up to 24 months of follow-up in patients with rheumatoid arthritis (RA) treated in Southern Italy. Patients’ data, activity index, and clinimetric scores were collected at baseline (T0), six (T6), twelve (T12), and twenty-four (T24) months following treatment initiation. At six, twelve, and twenty-four months, adverse events and treatment cessation were also recorded. Sixty-eight patients (mean age: 62.2±10.9 years; mean RA duration: 15±9.6 years) were enrolled over a period of 12 weeks. At baseline, twenty-four patients (35.3%) were treated with tofacitinib, and forty-four patients (64.7%) were treated with baricitinib. The baseline mean disease activity was moderate as measured by DAS28- ESR (5.0±1.0), DAS 28 CRP (4.69±0.94), and SDAI (26.87±10.73) score. Before beginning JAKinhibs therapy, thirty-two patients (61.8%) were taking bDMARDs, while the remaining thirty-six (38.2%) were bDMARDs-naïve. The 24-month retention rate for JAKinhibs was 91.1%. Six months after beginning treatment with JAKinhibs, a statistically significant improvement was observed in all evaluated activity indices and clinimetric scores. Improvement was confirmed during the 12- and 24-month follow-up evaluations. The positive correlation between baseline-T6 SDAI delta and discontinuation of JAKinhibs (p=0.02) suggests that RA worsening in the first six months may be a predictor of therapy withdrawal. Patients with RA responded favorably to tofacitinib and baricitinib in this prospective, real-world study from a single center in Southern Italy. Efficacy was observed despite an underlying persistent and treatment-resistant disease. | ||
| 650 | 4 | |a Rheumatoid Arthritis | |
| 650 | 4 | |a JAK inhibitors | |
| 650 | 4 | |a Tofacitinib | |
| 650 | 4 | |a Baricitinib | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Internal medicine | |
| 700 | 0 | |a N. Bertolini |e verfasserin |4 aut | |
| 700 | 0 | |a E. Mostacciuolo |e verfasserin |4 aut | |
| 700 | 0 | |a S. Passavanti |e verfasserin |4 aut | |
| 700 | 0 | |a J.M.E. Luppino |e verfasserin |4 aut | |
| 700 | 0 | |a A. Del Puente |e verfasserin |4 aut | |
| 700 | 0 | |a R. Peluso |e verfasserin |4 aut | |
| 700 | 0 | |a F. Santelli |e verfasserin |4 aut | |
| 700 | 0 | |a R. Scarpa |e verfasserin |4 aut | |
| 700 | 0 | |a L. Costa |e verfasserin |4 aut | |
| 700 | 0 | |a F. Caso |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Reumatismo |d PAGEPress Publications, 2012 |g 74(2022), 3 |w (DE-627)DOAJ000058424 |x 22402683 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2022 |g number:3 |
| 856 | 4 | 0 | |u https://doi.org/10.4081/reumatismo.2022.1511 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/36c0e1477318460fb40c0fe3656af5f6 |z kostenfrei |
| 856 | 4 | 0 | |u https://reumatismo.org/index.php/reuma/article/view/1511 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0048-7449 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2240-2683 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2022 |e 3 | ||